28 results about "Therapeutic Hormone" patented technology

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

Described herein are methods of treating a biochemical relapse patient of hormone-sensitive prostate cancer using a pharmaceutical product comprising an androgen receptor inhibitor, such as dalotamide.

The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.

Methods for treating hormonally driven disorders by administering the PI3K / mT0R inhibitor gedatolisib in combination with hormone therapy are provided. Hormonally driven disorders include, for example, prostate cancer and endometrial disorders. The treatment regimens can also include additional therapies, such as chemotherapy, surgery and / or administration of an immune checkpoint inhibitor(s), a receptor tyrosine kinase inhibitor, a CDK 4 / 6 inhibitor or an epigenetic-targeted therapy.

A composition contains β-glucan and is used for preventing and / or treating hormone-dependent dermatitis, skin mucositis or other skin inflammatory diseases.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a pharmaceutical composition for treating hormone-resistant severe asthma and application of the pharmaceutical composition. The invention relates to an application of pentagalloylglucose (PGG) in preparation of a medicine for treating or preventing hormone-resistant severe asthma. The traditional Chinese medicine composition has a better effect on emphysema caused by severe asthma. The invention reveals and verifies that intestinal injury is a key upstream factor causing severe asthma and hormone resistance for the first time. Through targeted repair of intestinal tracts, the PGG can fundamentally remodel the immune microenvironment of the lung, and creates conditions for hormone to play a role. The discovery breaks through the limitation that traditional asthma treatment only focuses on local targets of the respiratory tract, and a brand new theoretical basis and a feasible solution are provided for overcoming the worldwide problem of hormone resistance.

To provide: diarylhydantoin compounds, including diarylthiohydantoins; methods for synthesizing them; and methods for using them in the treatment of hormone refractory prostate cancer.SOLUTION: A method for treating a hyperproliferative disorder comprises administering a pharmaceutical composition of the present invention to a subject in need of such treatment, thereby treating the hyperproliferative disorder. The invention provides a series of compounds having strong antagonistic activities with minimal agonistic activities against AR.SELECTED DRAWING: None

To provide a combination therapy for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.SOLUTION: Provided is a method comprising administering a combination therapy including ipatasertib, fulvestrant, and a CDK4 / 6 inhibitor over a 28-day cycle.SELECTED DRAWING: Figure 1A

The present disclosure relates to compositions and methods for treating hormone receptor positive (HR+) cancer with (Z)-endoxifen and a CDK4 / 6 inhibitor, such as abemaciclib. The disclosure is based on the discovery that (Z)-endoxifen and abemaciclib have synergistic effects on reducing tumor growth and proliferation in breast cancer models. The disclosure also provides fixed dose combinations of (Z)-endoxifen and abemaciclib, which offers advantages in terms of convenience and compliance. The compositions and methods are suitable for treating subjects with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer, especially those who are contraindicated for aromatase inhibitor therapy and / or ovarian suppression therapy.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifin, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The invention provides a cortex phellodendri composition for treating facial hormone-dependent dermatitis and a preparation method of the cortex phellodendri composition, and relates to the technical field of traditional Chinese medicines. The golden cypress composition is prepared from the following traditional Chinese medicines in parts by weight: 5-15 parts of golden cypress, 3-10 parts of fructus forsythiae, 2-7 parts of honeysuckle, 2-7 parts of oriental wormwood, 1-4 parts of dandelion and 0.5-2 parts of cassia twig. The cortex phellodendri composition disclosed by the invention can be used for treating hormone-dependent dermatitis after being coated or pasted on the face, and is quick in effect taking, good in effect and not easy to relapse.

We disclose a pharmaceutical composition adapted for oral delivery comprising native testosterone; a treatment regimen comprising administration of the composition(s); and methods and uses for the treatment of hormone related conditions such as hypogonadism in human male, female and transgender subjects.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.

Methods for treating hormonally driven disorders by administering the PI3K / mTOR inhibitor gedatolisib in combination with hormone therapy are provided. Hormonally driven disorders include, for example, prostate cancer and endometrial disorders. The treatment regimens can also include additional therapies, such as chemotherapy, surgery and / or administration of an immune checkpoint inhibitor(s), a receptor tyrosine kinase inhibitor, a CDK 4 / 6 inhibitor or an epigenetic-targeted therapy.

A drug for preventing or treating steroid-induced osteonecrosis of the femoral head, comprising an active ingredient cycloastragenol. The drug can remarkably improve intraosseous blood supply in the steroid-induced osteonecrosis of the femoral head, reduce formation of necrotic areas and empty lacunae, decrease excessive bone resorption and reduce CTSK protein expression, and provide a potential prevention and treatment scheme for treatment of steroid-induced osteonecrosis of the femoral head.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

The present invention relates to compounds capable of inhibiting TRIM24 activity and their use in combination with androgen deprivation therapy and / or androgen receptor signaling inhibitors and / or any type of AR inhibitor (e.g., pharmacological AR degrader) in a method of treatment of a hormone-sensitive metastatic prostate cancer, in particular in prostate cancer that are characterized by recurrent point mutations in SPOP. Moreover, the invention posits the use of inhibiting TRIM24 activity for the treatment of AR-V7-driven castration-resistant prostate cancer (CRPC).

The present invention relates to compounds capable of inhibiting TRIM24 activity and their use in combination with androgen deprivation therapy and / or androgen receptor signaling inhibitors and / or any type of AR inhibitor (e.g., pharmacological AR degrader) in a method of treatment of a hormone-sensitive metastatic prostate cancer, in particular in prostate cancer that are characterized by recurrent point mutations in SPOP. Moreover, the invention posits the use of inhibiting TRIM24 activity for the treatment of AR-V7-driven castration-resistant prostate cancer (CRPC).

The present invention provides the use of all-trans retinoic acid (ATRA) combined with low-dose rituximab in the preparation of a medicament for treating steroid-resistant or recurrent ITP. The dosage of rituximab is 100 mg weekly; the dosage of ATRA is 20 mg per square meter of body surface area per day. A multicenter randomized controlled trial demonstrated that the combination of ATRA and LD-RTX demonstrated superior efficacy and safety compared to LD-RTX alone in the treatment of patients with steroid-resistant or recurrent ITP.

The present invention relates to novel salts, particularly crystalline salts, of 5-((1-(methylsulfonyl)piperidin-4-yl)methoxy)-2-((5-(trifluoromethyl)isoindolin-2-yl)methyl)-4H-pyran-4-one (I) which are particularly suitable for use in the manufacture of pharmaceutical compositions. Furthermore, the invention relates to pharmaceutical compositions comprising such novel salts. Compound (I) is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated cancers, such as prostate cancer and breast cancer.

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoin, as well as methods for their synthesis and use in the treatment of hormone refractory prostate cancer.

The present invention relates to a quinazoline carboxamide azetidine compound, and to pharmaceutical combinations and compositions comprising such a compound preferably together with at least one distinct therapeutic agent, preferably anti-cancer agent, as well as to uses thereof for treating a disease, preferably a cancer, even more preferably estrogen receptor-positive (ER+) cancer, in particular in a subject resistant to endocrinal therapy.

The present disclosure relates to a method for treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), metastatic or locally recurrent breast cancer, comprising administering to a patient afflicted with such cancer a next-generation selective estrogen receptor degrading drug (ngSERD), e.g., camizestrant, wherein the cancer has recurred or progressed after at least one prior course of endocrine therapy.

The present disclosure provides industrially scalable methods of making (Z)-endoxifen or a salt thereof, crystalline forms of endoxifen, and compositions comprising them. The present disclosure also provides methods for treating hormone-dependent breast and hormone-dependent reproductive tract disorders.

Described herein are methods of treating hormone receptor positive breast cancer in a patient which include concomitantly administering an initial neoadjuvant or adjuvant IV chemotherapy cycle and an initial dose of a 3.6 mg goserelin acetate implant to the patient, or concomitantly administering an initial dose of a 3.6 mg goserelin acetate implant to the patient with a first of a plurality of long-term IV chemotherapy cycles. After one or more doses of the 3.6 mg goserelin acetate implant, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days. Also included are methods of improving patient compliance, increasing duration of treatment, and / or reducing the need for oophorectomy in a patient with hormone receptor positive breast cancer by administering a 3.6 mg goserelin acetate implant to the patient, and upon the patient becoming nonadherent, the 3.6 mg goserelin acetate implant is discontinued, and the patient is then administered a 10.8 mg goserelin implant once every 84 to 108 days.

The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers. The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

The present invention relates to the technical field of medical devices, and particularly to a variable-frequency electric field generating system and its application in the treatment of pathological angiogenesis, including: an alternating current power generator for generating a sine wave signal with a frequency of 500 - 1500 kHz and an amplitude of 50 - 100 Vpp; a wire, the first end of which is connected to the output end of the alternating current power generator. The present invention suppresses the generation of pro-angiogenic factors at the lesion site by generating a medium-high frequency alternating electric field, and has a better effect on suppressing pathological angiogenesis. Compared with the prior art (such as bevacizumab, injection sclerosing agent, endovascular interventional embolization, surgical resection, radiotherapy, hormone therapy, etc.), the device of the present invention suppresses pathological angiogenesis through an alternating electric field, and has the advantages of non-invasive (used on the body surface) or minimally invasive (implanted in the body), safe, locally applied, no systemic adverse reactions, pure physical and pollution-free, etc.

A composition comprising: (i) a monocyclic sesquiterpene alcohol; (ii) vitamin B or a derivative thereof; and (iii) an amide of formula (I) wherein X is CH or N, Y is CHR8 or O, n is 0, 1 or 2, preferably 1 or 2, R1, R2 and R3 are independently from each other selected from the group consisting of H, OH, a halogen atom, a carbamoyl group and a C1-C6 alkyl group, and R4, R5, R6, R7 and R8 are independently from each other H or a C1-C6 alkyl group. The composition is suitable for topical application to treat hormone-affected skin. # imgabs0 #